Tenecteplase for acute stroke: the thrombolysis puzzle
- PMID: 35525249
- DOI: 10.1016/S1474-4422(22)00172-7
Tenecteplase for acute stroke: the thrombolysis puzzle
Conflict of interest statement
SBC is the Principal investigator of the TEMPO-2 trial, for which Boehringer Ingelheim provides study drug (tenecteplase). AYXY declares funding support from the Heart & Stroke Foundation of Canada and the Canadian Institutes of Health Research.
Comment on
-
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.Lancet Neurol. 2022 Jun;21(6):511-519. doi: 10.1016/S1474-4422(22)00124-7. Epub 2022 May 4. Lancet Neurol. 2022. PMID: 35525250 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
